News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,459 Results
Type
Article (13764)
Company Profile (101)
Press Release (251594)
Section
Business (88105)
Career Advice (465)
Deals (15351)
Drug Delivery (67)
Drug Development (36616)
Employer Resources (51)
FDA (6291)
Job Trends (6226)
News (150319)
Policy (14034)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23234)
ALS (36)
Alzheimer's disease (389)
Antibody-drug conjugate (ADC) (37)
Approvals (6328)
Artificial intelligence (104)
Autoimmune disease (8)
Automation (3)
Bankruptcy (149)
Best Places to Work (4397)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (74)
Cancer (585)
Cardiovascular disease (70)
Career advice (407)
Career pathing (11)
CAR-T (21)
Cell therapy (85)
Cervical cancer (4)
Clinical research (30894)
Collaboration (325)
Compensation (138)
Complete response letters (17)
COVID-19 (757)
CRISPR (19)
C-suite (117)
Cystic fibrosis (35)
Data (604)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1317)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32092)
Editorial (11)
Employer branding (5)
Employer resources (44)
Events (37452)
Executive appointments (359)
FDA (6688)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (205)
Gene editing (37)
Generative AI (8)
Gene therapy (99)
GLP-1 (339)
Government (1286)
Grass and pollen (2)
Guidances (15)
Healthcare (3577)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (790)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (13)
Intellectual property (45)
Interviews (59)
IPO (5877)
IRA (29)
Job creations (2053)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3431)
Liver cancer (19)
Lung cancer (79)
Lymphoma (52)
Machine learning (1)
Management (16)
Manufacturing (143)
MASH (31)
Medical device (1277)
Medtech (1279)
Mergers & acquisitions (9662)
Metabolic disorders (246)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (22)
Neuropsychiatric disorders (6)
Neuroscience (561)
NextGen: Class of 2025 (1590)
Non-profit (596)
Northern California (679)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (44)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28899)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8045)
Phase II (13068)
Phase III (11727)
Pipeline (414)
Podcasts (46)
Policy (59)
Postmarket research (1402)
Preclinical (3210)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (158)
Real estate (2638)
Recruiting (18)
Regulatory (10094)
Reports (14)
Research institute (567)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (36)
Series B (11)
Service/supplier (3)
Sickle cell disease (31)
Southern California (695)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1628)
State (2)
Stomach cancer (3)
Supply chain (28)
Tariffs (10)
The Weekly (29)
United States (6896)
Vaccines (150)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (43)
Last 7 days (273)
Last 30 days (969)
Last 365 days (12055)
2025 (3078)
2024 (12524)
2023 (14266)
2022 (19576)
2021 (20083)
2020 (19047)
2019 (14918)
2018 (11748)
2017 (13895)
2016 (13135)
2015 (15483)
2014 (12427)
2013 (10596)
2012 (11405)
2011 (11931)
2010 (10890)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (56)
Arkansas (3)
Asia (20090)
Australia (2605)
California (1641)
Canada (874)
China (229)
Colorado (65)
Connecticut (65)
Delaware (53)
Europe (39402)
Florida (306)
Georgia (36)
Idaho (9)
Illinois (186)
India (15)
Indiana (128)
Iowa (1)
Japan (86)
Kansas (59)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (245)
Massachusetts (1422)
Michigan (28)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (725)
New Mexico (7)
New York (482)
North Carolina (380)
North Dakota (2)
Northern California (679)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (415)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (695)
Tennessee (34)
Texas (219)
Utah (33)
Virginia (70)
Washington D.C. (29)
Washington State (112)
Wisconsin (14)
265,459 Results for "overland pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
Allogene Therapeutics, Inc. announced it will restate previously issued financial statements for the years ended December 31, 2020, 2021 and 2022 and interim quarters during 2022 and 2023 due to non-cash accounting adjustments associated with the December 2020 formation of the Allogene Overland Biopharm joint venture in Asia.
February 16, 2024
·
3 min read
Business
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: ADCT), today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA.
July 24, 2023
·
8 min read
BioMidwest
Overland Park Regional Medical Center Becomes First U.S. Hospital with Two Stereotaxis Robotic Systems for Arrhythmia Treatment
Stereotaxis announced that physicians at Overland Park Regional Medical Center launched and successfully completed the first procedures using the advanced Genesis Robotic Magnetic Navigation System.
August 30, 2023
·
4 min read
Business
Overland Pharmaceuticals Appoints Dr. Xun Liu as Chief Technology Officer
Overland Pharmaceuticals (“Overland”), a premier biopharmaceutical company bringing innovative medicines to patients in Asia and worldwide, today announced the appointment of Xun Liu, Ph.D., as Chief Technology Officer (CTO).
March 1, 2022
·
3 min read
Biotech Bay
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
Allogene Overland Biopharm, a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced it has completed the buildout of its state-of-the-art AlloCAR T manufacturing facility in Shanghai, China.
October 31, 2022
·
4 min read
BioMidwest
Medline expands mobility portfolio with byACRE Overland Carbon all-terrain rollator
Medline has expanded its broad consumer portfolio of mobility products with the inclusion of the new byACRE Overland Carbon Fiber Rollator, a lightweight assistive walking device durable and agile enough to operate in snow, sand and mud, as well as on sidewalks, curbs, unpaved trails and thick grass.
December 8, 2022
·
3 min read
Business
Overland Pharmaceuticals Partners with ArisGlobal to Accelerate Safety Capabilities
ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end drug development technology platform LifeSphere® announced its partnership with Overland Pharmaceuticals.
December 7, 2021
·
3 min read
Business
Overland Pharmaceuticals Appoints Ed Zhang as Chief Executive Officer and Welcomes Industry Leaders John Maraganore and Peter Ho as Strategic Advisors
Overland Pharmaceuticals today announced the appointment of Co-founder Ed Zhang , MBA as full-time Chief Executive Officer after serving as Interim Chief Executive Officer since May 2021.
January 18, 2022
·
6 min read
Business
Overland Pharmaceuticals Appoints Roger Luo, Ph.D. as Chief Development Officer
Overland Pharmaceuticals, a premier biopharmaceutical company bringing innovative medicines to patients in Asia and worldwide, announced the appointment of Roger Luo, Ph.D. as Chief Development Officer, Head of Clinical and Preclinical Development.
August 2, 2021
·
3 min read
BioMidwest
Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Overland Park Regional Medical Center (OPRMC) is establishing its second robotic program for the treatment of heart rhythm disorders.
September 13, 2022
·
3 min read
1 of 26,546
Next